The potential impact on the Medicaid program is less clear. Although there is no statutory requirement for rulemaking under the Medicaid program similar to that for Medicare, the federal government also has more limited control over the direction of individual states’ Medicaid program offerings.
The ACR is steadfastly committed to ensuring that rheumatologists and rheumatology health professionals have a strong voice in rulemaking by federal agencies. We will continue to closely monitor any changes to the NIH grant-making processes and the agency’s overall structure, as well as the court challenges that have sought to stop or reverse some of the recent decisions that have significantly impacted the agency’s ability to fund public health research. ACR/ARP members should email the ACR’s advocacy team at [email protected] with any questions and comments they may have.
